Our industry-leading neuroscience portfolio includes FDA-approved treatments for major depressive disorder, excessive daytime sleepiness associated with narcolepsy and obstructive sleep apnea, and migraine, and multiple late-stage development programs addressing a broad range of serious neurological and psychiatric conditions that impact over 150 million people in the United States. May assist in the development/revision and/or provide input in the development of clinical trial related documents including but not limited to study tools, monitoring tools, presentations, meeting materials, case report forms, informed consents, timelines, clinical monitoring plans, site reference manuals, pharmacy manuals, laboratory manuals, protocols, and training materials.